Literature DB >> 33255593

The Genetic Complexity of Prostate Cancer.

Eva Compérat1,2,3, Gabriel Wasinger3, André Oszwald3, Renate Kain3, Geraldine Cancel-Tassin1, Olivier Cussenot1,4.   

Abstract

Prostate cancer (PCa) is a major concern in public health, with many genetically distinct subsets. Genomic alterations in PCa are extraordinarily complex, and both germline and somatic mutations are of great importance in the development of this tumor. The aim of this review is to provide an overview of genetic changes that can occur in the development of PCa and their role in potential therapeutic approaches. Various pathways and mechanisms proposed to play major roles in PCa are described in detail to provide an overview of current knowledge.

Entities:  

Keywords:  ERG; PTEN; TMPRSS2; androgen receptors; germline mutations; prostate cancer; somatic mutations

Mesh：

Year:  2020        PMID： 33255593      PMCID： PMC7760266          DOI： 10.3390/genes11121396

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN： 2073-4425            Impact factor:   4.096


  67 in total

1.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer.

Authors:  A Brandt; J Sundquist; K Hemminki
Journal:  Ann Oncol       Date:  2011-04-05       Impact factor: 32.976

Review 4.  Prognostic outlier genes for enhanced prostate cancer treatment.

Authors:  Hyun Kim; Jenna Skowronski; Robert B Den
Journal:  Future Oncol       Date:  2016-10-12       Impact factor: 3.404

5.  The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.

Authors:  Atsushi Mizokami; Eitetsu Koh; Hiroshi Fujita; Yuji Maeda; Masayuki Egawa; Kiyoshi Koshida; Seijiro Honma; Evan T Keller; Mikio Namiki
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

6.  Tracking the clonal origin of lethal prostate cancer.

Authors:  Michael C Haffner; Timothy Mosbruger; David M Esopi; Helen Fedor; Christopher M Heaphy; David A Walker; Nkosi Adejola; Meltem Gürel; Jessica Hicks; Alan K Meeker; Marc K Halushka; Jonathan W Simons; William B Isaacs; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  J Clin Invest       Date:  2013-10-25       Impact factor: 14.808

7.  A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data.

Authors:  Minh-Phuong Huynh-Le; Chun Chieh Fan; Roshan Karunamuni; Eleanor I Walsh; Emma L Turner; J Athene Lane; Richard M Martin; David E Neal; Jenny L Donovan; Freddie C Hamdy; J Kellogg Parsons; Rosalind A Eeles; Douglas F Easton; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch Garcia; Kenneth Muir; Henrik Grönberg; Fredrik Wiklund; Markus Aly; Johanna Schleutker; Csilla Sipeky; Teuvo Lj Tammela; Børge Grønne Nordestgaard; Timothy J Key; Ruth C Travis; Paul D P Pharoah; Nora Pashayan; Kay-Tee Khaw; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Dominika Wokolorczyk; Wojciech Kluzniak; Lisa A Cannon-Albright; Hermann Brenner; Ben Schöttker; Bernd Holleczek; Jong Y Park; Thomas A Sellers; Hui-Yi Lin; Chavdar Kroumov Slavov; Radka P Kaneva; Vanio I Mitev; Jyotsna Batra; Judith A Clements; Amanda B Spurdle; Manuel R Teixeira; Paula Paulo; Sofia Maia; Hardev Pandha; Agnieszka Michael; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-06-24       Impact factor: 4.254

Review 8.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

9.  Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.

Authors:  Laura S Graham; Bruce Montgomery; Heather H Cheng; Evan Y Yu; Peter S Nelson; Colin Pritchard; Stephanie Erickson; Ajjai Alva; Michael T Schweizer
Journal:  PLoS One       Date:  2020-05-26       Impact factor: 3.240

10.  Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.

Authors:  R K Nam; L Sugar; W Yang; S Srivastava; L H Klotz; L-Y Yang; A Stanimirovic; E Encioiu; M Neill; D A Loblaw; J Trachtenberg; S A Narod; A Seth
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640
View more
  2 in total

1.  HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.

Authors:  Valentí Gómez; Myria Galazi; Gregory Weitsman; James Monypenny; Fahad Al-Salemee; Paul R Barber; Kenrick Ng; Richard Beatson; Bálint Szokol; László Orfi; Greg Mullen; Bart Vanhaesebroeck; Simon Chowdhury; Hing Y Leung; Tony Ng
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.261

2.  Contribution of CD4+ T cell-mediated inflammation to diarrhea in patients with COVID-19.

Authors:  Xiaobing Wang; Jia Wei; Ruiping Zhu; Liping Chen; Feng Ding; Rui Zhou; Liuqing Ge; Jun Xiao; Qiu Zhao
Journal:  Int J Infect Dis       Date:  2022-04-06       Impact factor: 12.074
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.